Donanemab, a new drug developed by Eli Lilly for the treatment of early forms of Alzheimer's disease, has received a favorable opinion from the EMA committee, recommending its authorization. The drug, which is intended for patients who are non-carriers or heterozygous for apolipoprotein E ε4, has been shown in clinical trials to slow the progression of cognitive impairment. The drug will be available as an infusible solution, and common side effects include amyloid-associated imaging abnormalities and headache. The final authorization decision rests with the European Commission.
Sources
Un nou tratament pentru boala Alzheimer în stadii timpurii, aproape de autorizare în UE
Un medicament pentru tratamentul bolii Alzheimer în stadii timpurii, aproape de autorizare în UE
Un medicament pentru tratamentul bolii Alzheimer în stadii timpurii, aproape de autorizare în UE
Latest News
14:03
DNA: Cristina Trăilă, prosecuted for complicity in the use of influence
14:01
The lawyers of the Tate brothers claim that their opulent image is a marketing strategy / The cars and luxury goods would have been rented.
14:01
Cluj-Napoca: 40 electric buses put into circulation, purchased with funding of 34 million euros through PNRR and POR
13:49
Romeo Lungu stated that Mayor Constantin Toma will not be excluded from the PSD, although he has decided not to run for a new term on behalf of the party.
13:36
Cancer patients are complaining of a crisis of chemotherapy drugs on the market in Romania, the head of CNAS claims that "everything is fine".
See more news